<<  Back

Harvard Bioscience, Inc. Invites You to Join Its Fourth Quarter and Year Ended 2000 Conference Call on the Web

Feb 14,2001
Harvard Bioscience, Inc. Invites You to Join Its Fourth Quarter and Year Ended 2000 Conference Call on the Web

HOLLISTON, Mass., Feb. 14 /PRNewswire/ -- Harvard Bioscience, Inc. (Nasdaq: HBIO) You are invited to listen to our fourth quarter and year ended 2000 conference call. It will be broadcast live over the Internet on Friday, February 23 at 10:00 a.m., EST. Chane Graziano, CEO, David Green, President, and Jim Warren, CFO will conduct the call. We will issue our earnings release on Thursday, February 22 at 6:00 p.m., EST.

To listen to the conference call, log on to the web at:

http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=HBIO&script=2100

This address will take you directly to the correct page of our web site where you will find the web cast icon. Or, you can go to our web site, www.harvardbioscience.com, click on the investor relations button and then click on the web cast icon.

If you are unable to listen to the live webcast the call will be archived for two weeks on our web site.

Harvard Bioscience is a global developer, manufacturer and marketer of innovative, enabling tools in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. We sell approximately 10,000 products to thousands of researchers in over 60 countries though our 1,000 page catalog, and through our distributors, the most notable of which is AP Biotech. We have sales and manufacturing operations in the United States, the United Kingdom, and Germany and sales offices in France and Canada.

Statements in this release that relate to expectations and objectives of management for future operations of Harvard Bioscience, Inc., or that otherwise relate to future performance, are forward looking statements. Actual results may differ from those projected as a result of product demand, pricing, market acceptance, economic conditions, intellectual property issues, competitive products, risks in product and technology development, and other risks identified in our Securities and Exchange Commission fillings.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site, http://www.harvardbioscience.com. SOURCE Harvard Bioscience, Inc.

CONTACT: Jim Warren, CFO, jwarren@harvardbioscience.com, or David Green, President, dgreen@harvardbioscience.com, or Chane Graziano, CEO, cgraziano@harvardbioscience.com, all of Harvard Bioscience, Inc./



Disclaimer:
The information contained within this and other Harvard Bioscience Web pages should be deemed accurate and current as of the date of the most recent update, or if no update information has been provided, the date of issuance. Harvard Bioscience assumes no responsibility for any misincurrances or misstatements which occur as the result of the reading of dated material. Users are strongly encouraged to check dates of issuance and most recent update of any information contained within, or linked to, Harvard Bioscience’s web site. For Harvard Bioscience’s most current information please reference Harvard Bioscience public filings with the Securities and Exchange Commission located at http://www.sec.gov.